Catalyst Funds Management Pty LTD Nuvalent, Inc. Transaction History

Catalyst Funds Management Pty LTD

  • $382 Billion
  • Q1 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Dec 04, 2024
BUY
$72.35 - $88.99 $65,114 - $80,091
900 New
900 $67.6 Million

About Nuvalent, Inc.

NUVL Quotes by TradingView
  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.4B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Catalyst Funds Management Pty LTD Portfolio

Follow Catalyst Funds Management Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Funds Management Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Funds Management Pty LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email